Vitamin D and Lyme Disease
Lyme disease is a tick-borne bacterial infection caused by Borrelia burgdorferi. Standard treatment (doxycycline, amoxicillin, cefuroxime) is highly effective in early Lyme. A subset of patients develop post-treatment Lyme disease syndrome (PTLDS) with persistent fatigue, arthralgia, and cognitive symptoms. Vitamin D's role is primarily as a modifier of PTLDS symptoms via general immune adequacy.
Vitamin D in PTLDS
Cross-sectional studies find lower 25(OH)D in PTLDS patients than matched controls, though most PTLDS cohorts share generic chronic-illness characteristics (reduced outdoor time, dietary changes, indoor lifestyle shifts). Correction is reasonable general care.
The Marshall protocol controversy
The "Marshall Protocol" claims chronic Lyme (and other infections) is a condition of vitamin D dysregulation, treated by very-low-vitamin D intake plus antibiotics and olmesartan. This protocol has no rigorous evidence base, contradicts established vitamin D physiology, and is rejected by mainstream infectious-disease specialists. Do not follow it.
Evidence-based Lyme management
- Early localised Lyme (erythema migrans): doxycycline 100 mg BID × 10-14 days is first-line.
- Later Lyme with cardiac, neurologic, or arthritic involvement: 21-28 days doxycycline or IV ceftriaxone.
- Post-treatment persistent symptoms: rehabilitation, symptom-directed therapy; extended antibiotic courses have not shown benefit in RCTs and carry risk.
- Vitamin D correction in the deficient is reasonable adjunctive care.
Prevention
- DEET or permethrin-treated clothing in endemic areas.
- Tick checks after outdoor activity in endemic regions.
- Prompt tick removal (within 24-36 hours minimises transmission risk).
- Post-exposure prophylaxis (single doxycycline dose within 72 hours) for high-risk tick bites.